Vericel Reports 1Q19 MACI Revenue of $16.6MM, +37% vs. 1Q18

Vericel reports 1Q19 MACI revenue of USD $16.6MM, +37% vs. 1Q18.

• Biopsy and implant trends indicate that MACI is on track to potentially exceed previous guidance
• The company provided revised guidance for MACI and Epicel combined, raising it to $100MM to $114MM, up from $108MM to $112MM; MACI is expected to account for at least $90MM of the updated guidance
• Expanded MACI salesforce now deployed into the field, bringing total number of sales territories to 48

MACI sales and growth on an as-reported basis ($MM):

Net earnings ($MM):

Sources: Vericel; ORTHOWORLD estimates

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.